CTNM

Business Context and Reporting Period

Company: Contineum Therapeutics, Inc. (CTNM)
Filing Type: Form 10-Q (Unaudited)
Period: Three months ended March 31, 2026
Business Overview: Contineum is a clinical-stage biopharmaceutical company developing therapies for neuroscience, inflammation, and immunology (NI&I) indications. The company operates as a single reportable segment and is classified as an emerging growth company and a smaller reporting company. It has no approved products and has not generated product revenue.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Improvement: Net loss decreased by $1.5 million (9.6%) compared to Q1 2025, primarily driven by a $2.1 million reduction in R&D expenses.
• R&D Expense Reduction: R&D costs declined due to the completion of the VISTA Phase 2 trial for PIPE-307 (RRMS) and the Phase 1b PET trial for PIPE-791. These decreases were partially offset by increased costs for the Phase 2 trial of PIPE-791 for idiopathic pulmonary fibrosis (IPF).
• G&A Expense Increase: G&A expenses rose by $0.9 million, attributed to higher stock-based compensation ($0.6 million) and increased personnel-related costs.
• Liquidity Position: Cash and marketable securities increased significantly from $262.3 million (total financial assets at Dec 31, 2025) to $246.3 million (cash, cash equivalents, and marketable securities at Mar 31, 2026) following a $93.0 million follow-on public offering in December 2025. However, cash and cash equivalents specifically dropped from $75.6 million to $20.2 million due to net investing outflows of $39.3 million for marketable securities purchases.

Outlook, Risks, and Management Commentary

• Clinical Progress:
  • PIPE-791 (LPA1R inhibitor): Positive top-line data announced in April 2026 from a Phase 1b trial for chronic pain, meeting primary safety endpoints and showing encouraging efficacy trends. A Phase 2 trial for IPF was initiated in December 2025.
  • PIPE-307 (M1R inhibitor): The Phase 2 VISTA trial for relapse-remitting multiple sclerosis (RRMS) did not meet primary or secondary efficacy endpoints, though safety was acceptable. J&J retains sole discretion to continue development. J&J is recruiting for the Phase 2 Moonlight-1 trial for major depressive disorder (MDD), expected to complete in June 2026.
• Capital Resources: Management believes existing cash, cash equivalents, and marketable securities ($246.3 million) are sufficient to fund operations for at least 12 months. The company amended its ATM Sales Agreement in March 2026 to increase the offering capacity to $100.0 million (exclusive of prior sales).
• Risks and Contingencies:
  • Financing Risk: Future funding is required to continue development; failure to secure financing could lead to delays or termination of programs.
  • Development Risk: High uncertainty regarding clinical trial outcomes and regulatory approval. The failure of the PIPE-307 RRMS trial highlights the risk of asset failure.
  • Collaboration Risk: J&J has sole discretion over the future development of PIPE-307; the company may not receive milestone payments or royalties if J&J elects not to proceed.

Investor Verification Checklist

• Cash Runway: Verify the specific monthly burn rate and confirm the 12-month liquidity estimate given the recent shift in cash allocation to marketable securities.
• PIPE-307 Status: Monitor J&J's decision on whether to proceed with the MDD program following the RRMS trial failure and the timeline for the Moonlight-1 trial completion.
• PIPE-791 Phase 2: Track enrollment and interim data from the ongoing Phase 2 IPF trial initiated in late 2025.
• ATM Utilization: Monitor the utilization of the amended $100 million ATM facility to assess future dilution risks.
• Stock-Based Compensation: Review the $40.9 million of unrecognized stock-based compensation and its impact on future operating expenses.